What is the recommended dose of Sulbactam (a beta-lactamase inhibitor) in pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Sulbactam Dosing in Pediatric Patients

For pediatric patients 1 year of age or older, the FDA-approved dose of ampicillin-sulbactam is 300 mg/kg/day (representing 200 mg/kg/day ampicillin plus 100 mg/kg/day sulbactam) administered intravenously in equally divided doses every 6 hours, with a maximum sulbactam dose not exceeding 4 grams per day. 1

Standard Dosing Regimen

  • The recommended dose is 300 mg/kg/day of the ampicillin-sulbactam combination (2:1 ratio), which translates to 200 mg/kg/day ampicillin and 100 mg/kg/day sulbactam, divided into doses given every 6 hours via IV infusion 1

  • Pediatric patients weighing 40 kg or more should receive adult dosing recommendations, with total sulbactam not exceeding 4 grams daily 1

  • The course of IV therapy should not routinely exceed 14 days, and most children transition to oral antimicrobials following initial IV treatment 1

Administration Guidelines

  • Each dose should be administered as a slow IV infusion over 15-30 minutes when diluted in 50-100 mL of compatible diluent 1

  • The safety and efficacy of intramuscular administration in pediatric patients have not been established 1

Specific Clinical Applications

Endocarditis

  • For pediatric endocarditis, the American Heart Association recommends 300 mg/kg/day IV divided into 4-6 equally divided doses for 4-6 weeks 2

Intra-abdominal Infections

  • For complicated intra-abdominal infections, 200 mg/kg/day of ampicillin-sulbactam given every 6 hours is recommended 2

Omphalitis in Neonates

  • The American Academy of Pediatrics recommends ampicillin-sulbactam 200 mg/kg/day IV divided every 6 hours for neonatal omphalitis 3

Pharmacokinetic Considerations

  • Pharmacokinetic studies demonstrate that ampicillin and sulbactam achieve mean peak concentrations of 177-200 mcg/mL and 82-102 mcg/mL respectively in pediatric patients aged 1-12 years 4

  • The mean half-life is approximately 0.77 hours for ampicillin and 0.81 hours for sulbactam, comparable to adult values 4

  • Age does not significantly affect the pharmacokinetics of either drug in children 1-12 years old 4

Dosing for Severe or Resistant Infections

  • For empiric therapy of community-acquired pneumonia where MIC90 values are high (≥2 mcg/mL), the maximum FDA-approved dosage of 75 mg/kg four times daily may provide better coverage than lower doses 5

  • This higher dosing achieves the pharmacodynamic target of 50% fT>MIC against common respiratory pathogens including Streptococcus pneumoniae and Haemophilus influenzae 5

Renal Impairment Adjustments

  • In pediatric patients with renal impairment, dosing frequency should be reduced based on creatinine clearance, similar to adult recommendations 1:
    • CrCl ≥30 mL/min: Every 6-8 hours
    • CrCl 15-29 mL/min: Every 12 hours
    • CrCl 5-14 mL/min: Every 24 hours

Common Pitfalls to Avoid

  • Do not use intramuscular administration in pediatric patients, as safety and efficacy have not been established 1

  • Avoid underdosing in severe infections—the standard 300 mg/kg/day may be insufficient for pneumonia caused by organisms with higher MICs, where 75 mg/kg four times daily is preferred 5

  • Do not exceed 4 grams per day of the sulbactam component, even in patients weighing >40 kg 1

  • Ensure proper dilution and infusion time (15-30 minutes) to minimize adverse reactions 1

Safety Profile

  • Ampicillin-sulbactam is well tolerated in pediatric patients, with cure rates of 98.7% reported in clinical studies 6

  • Adverse reactions are uncommon, with rash being the most frequently reported side effect, rarely requiring discontinuation 6

  • The combination demonstrates lower nephrotoxicity compared to polymyxin-based therapies when treating resistant organisms 7

References

Guideline

Unasyn Dosing Guidelines for Specific Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Amoxicillin Dosing for Omphalitis in Infants

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pharmacokinetics of ampicillin and sulbactam in pediatric patients.

Antimicrobial agents and chemotherapy, 1999

Research

Sulbactam/ampicillin in the treatment of pediatric infections.

Diagnostic microbiology and infectious disease, 1989

Guideline

High-Dose Sulbactam Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.